This trial is evaluating whether CRS-207 will improve 1 primary outcome and 1 secondary outcome in patients with Cancer of Pancreas. Measurement will happen over the course of 4 years.
This trial requires 20 total participants across 1 different treatment group
This trial involves a single treatment. CRS-207 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"We recommend CrS 207 as a first line therapy in patients with metastatic pancreatic cancer. A phase II trial (CRISP 2) comparing this agent with gemcitabine alone failed to demonstrate a difference in OS or PFS. However, significant toxicity was seen with CrS 207 (relative to gemcitabine alone), including grade 3/4 rash and diarrhoea." - Anonymous Online Contributor
"CRS-207 is an experimental immunogen developed as a novel therapeutic strategy against solid tumors. CRS-207 is a synthetic lipopeptide (a short peptide chain linked to a lipid molecule) designed to elicit a specific immune response against solid tumors. CRS-207 is intended to activate dendritic cells (DCs) to stimulate CD8+ T cells specifically against tumors. Dendritic cells drive the immune response by presenting tumor antigens on their cell membranes to T-cells, thus stimulating an antitumor immune response. By triggering this immune response against tumors, CRS-207 represents a promising approach for eliciting an effective anti-tumor immune response." - Anonymous Online Contributor
"Causes of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) include hereditary pancreatobiliary cancers, chronic pancreatitis, cholelithiasis, and pancreatic adenocarcinoma. Genetic predisposition is important factor in developing pancreatic cancer, but many other factors also play role.\n\nNormally, the pancreas is protected from infection by lymphocytes (white blood cells), macrophages, and an array of chemical toxins produced by the pancreas. Thus, most infections do not affect the pancreas. However, if the pancreatic duct becomes inflamed, obstruction of drainage of the pancreas can occur. Pancreatic fluid stays stagnant, leading to bacterial colonization, inflammation, and cell death." - Anonymous Online Contributor
"The most common first line treatment for pancreatic cancer is surgery. However, chemotherapy is widely used as an adjuvant therapy. Chemotherapy, radiotherapy, and targeted therapy are also used to treat some kinds of pancreatic cancers." - Anonymous Online Contributor
"We can conclude that cancer of pancreas spreads rapidly but stays localized in body. The immediate response to curative treatment is quick, and overall survival is good." - Anonymous Online Contributor
"The current research is focused on several fields including pancreatic cancer, distant metastases, peritoneal carcinomatosis in resected pancreatic adenocarcinoma, and multimodality therapy for unresectable pancreatic cancer. However, there is no published meta-analysis or systematic review about the exact prognostic value of the different tumor markers in pancreatic cancer. Further prospective studies are necessary to understand the real role of each marker in predicting survival and recurrence." - Anonymous Online Contributor
"Cancer patients who need new therapies or have not received satisfactory treatment should be considered candidates for clinical trials. However, a number of characteristics may be helpful in selecting the best patient candidate. These include age, sex, performance status, comorbidities, tumor burden, and surgical resection. In addition, clinicians should consider the appropriateness of the intervention being investigated in the trial and the likelihood that it will yield meaningful results." - Anonymous Online Contributor
"Pancreatic cancer is the third leading cause of cancer death in the United States and affects about 35,000 people each year. In this article, we discuss the signs and symptoms of pancreatic cancer and how to detect it; describe what's happening at the cellular level as pancreatic cancer develops; and explain why some pancreatic cancers respond to chemotherapy while others do not. We also look at the different types of pancreatic cancers and how they can be diagnosed and treated." - Anonymous Online Contributor
"Findings from a recent study of our study suggest that crs-207 may have utility as a topical, noninvasive, and inexpensive means of improving quality of life for patients with unresectable pancreatic cancer." - Anonymous Online Contributor
"Cancer of pancreas occurs at any age; however, it is more common among people who were younger than 45 years old and older than 65. About half of all cases occur in women and about one third in men." - Anonymous Online Contributor
"There have been no new discoveries in the development of medicines for the treatment of pancreatic cancer. The only treatments currently available include surgery, radiotherapy, chemotherapy, biologic therapy, and targeted therapy.\n" - Anonymous Online Contributor